Maraviroc - CAS 376348-65-1
Catalog number:
B0084-067502
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C29H41F2N5O
Molecular Weight:
513.67
COA:
Inquire
Targets:
CCR | HIV
Description:
Selective CCR5 antagonist
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-067502 50 mg $199 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
Selective CCR5 antagonist
Appearance:
White to Off-White Solid
Synonyms:
4,4-Difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl-d6)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide; UK 427857-d6;
Solubility:
Soluble to 75 mM in DMSO and to 100 mM in ethanol
Storage:
Store at +4°C
MSDS:
Inquire
Quality Standard:
In-house
Shelf Life:
24 months.
Quantity:
Grams-Kilos
Melting Point:
197-198(dec.)
InChIKey:
GSNHKUDZZFZSJB-HLMSNRGBSA-N
InChI:
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C
Canonical SMILES:
O=C(C1CCC(CC1)(F)F)N[C@H](c1ccccc1)CCN1C2CCC1CC(C2)n1c(C)nnc1C(C)C
1.Maraviroc, as a switch option, in HIV-1 infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first N(t)RTI+PI/r regimen. Week 48 results of the randomised, multicentre MARaviroc switCH study (MARCH).
Pett SL1, Amin J2, Horban A3, Andrade-Villanueva J4, Losso M5, Porteiro N6, Sierra Madero J7, Belloso W8, Tu E2, Silk D2, Kelleher A9, Harrigan R10, Clark A11, Sugiura W12, Wolff M13, Gill J14, Gatell J15, Fisher M16, Clarke A16, Ruxrungtham K17, Prazuck Clin Infect Dis. 2016 Apr 5. pii: ciw207. [Epub ahead of print]
BACKGROUND:  Alternative combination antiretroviral therapies in virologically suppressed HIV-infected patients experiencing side-effects and/or at ongoing risk of important co-morbidities from current therapy are needed. Maraviroc(MVC), a chemokine receptor-5(CCR5) antagonist, is a potential alternative component of therapy in those with R5-tropic virus.
2.Coaxially electrospun fiber-based microbicides facilitate broadly tunable release of maraviroc.
Ball C1, Chou SF1, Jiang Y1, Woodrow KA2. Mater Sci Eng C Mater Biol Appl. 2016 Jun 1;63:117-24. doi: 10.1016/j.msec.2016.02.018. Epub 2016 Feb 4.
Electrospun fibers show potential as a topical delivery system for vaginal microbicides. Previous reports have demonstrated delivery of anti-HIV and anti-STI (sexually transmitted infection) agents from fibers formulated using hydrophilic, hydrophobic, or pH-responsive polymers that result in rapid, prolonged, or stimuli-responsive release, respectively. However, coaxial electrospun fibers have yet to be evaluated as a highly tunable microbicide delivery vehicle. In this research, we explored the opportunities and limitations of a model coaxial electrospun fiber system to provide broad and tunable release rates for the HIV entry inhibitor maraviroc. Specifically, we prepared ethyl cellulose (EC)-shell and polyvinylpyrrolidone (PVP)-core fibers that were capable of releasing actives over a range of hours to several days. We further demonstrated simple and effective methods for combining core-shell fibers with rapid-release formulations to provide combined instantaneous and sustained maraviroc release.
3.The CD4/CD8 ratio is inversely associated with cIMT progression in HIV infected patients on antiretroviral treatment.
Bernal Morell E1, Serrano Cabeza J2, Muñoz A3, Marín I4, Masia M5, Gutierrez F6, Cano A7. AIDS Res Hum Retroviruses. 2016 Mar 22. [Epub ahead of print]
Inversion of the CD4/CD8 ratio (< 1) has been identified as a surrogate marker of immunosenescence, and an independent predictor of AIDS events in HIV infected patients and mortality in the general population. We aimed to assess the association between the CD4/CD8 ratio and carotid intima-media thickness (cIMT) progression in treated HIV-infected patients as a marker of coronary heart disease. A longitudinal study was conducted during three years in 96 virally suppressed HIV infected patients receiving antiretroviral treatment (ART). We analyzed the associations between the CD4/CD8 ratio, cardiovascular risk factors and antiretroviral treatment (ARV), and progression of subclinical atherosclerosis assessed using carotid cIMT at baseline and after three years. Finally, ninety-six patients completed the study. Seventy six (79.1%) patients were male, aged 44±10 years, 39 (40.6%) were on treatment with protease inhibitors; 49 (51.04%) with non-nucleoside reverse transcriptase inhibitors (NNRTI), 6 (6.
4.Maraviroc reduces neuropathic pain through polarization of microglia and astroglia - Evidence from in vivo and in vitro studies.
Piotrowska A1, Kwiatkowski K1, Rojewska E1, Makuch W1, Mika J2. Neuropharmacology. 2016 Apr 23. pii: S0028-3908(16)30164-2. doi: 10.1016/j.neuropharm.2016.04.024. [Epub ahead of print]
Recent studies suggest that CCR5 and its ligands are important regulators for the development of neuropathic pain and that their modulation can have some beneficial properties. Therefore, the aim of our study was to investigate the influence of maraviroc (MVC, a CCR5 antagonist) on glial polarization markers and intracellular signaling pathways in the spinal cord 7 days after chronic constriction injury (CCI) to the sciatic nerve and in primary glial cultures after LPS stimulation. Our results demonstrated that chronic intrathecal administration of MVC diminished neuropathic pain symptoms and nociceptive threshold ∼60 min after drug administration on days 3 and 7 post-CCI. MVC downregulated the levels of phosphorylated p38 MAPK, ERK1/2 and NF-κB proteins in the spinal cord and upregulated STAT3 in the dorsal root ganglia (DRG). Additionally, using Western blot analysis, we demonstrated that MVC effectively diminished "classical" activation markers: IL-1β, IL-18, IL-6 and NOS2 in the spinal cord.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CCR Products


CAS 624733-88-6 MK-0812

MK-0812
(CAS: 624733-88-6)

Potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes

CAS 887401-92-5 INCB 3284

INCB 3284
(CAS: 887401-92-5)

Potent, selective and orally bioavailable CCR2 antagonist with IC50 of 3.7 nM

CAS 149845-06-7 Saquinavir Mesylate

Saquinavir Mesylate
(CAS: 149845-06-7)

Saquinavir is an HIV Protease Inhibitor used in antiretroviral therapy. It inhibits both HIV-1 and HIV-2 proteases. Studies have also looked at saquinavir as a ...

AZD-5672
(CAS: 780750-65-4)

AZD5672 is CCR5 receptor antagonist originated by AstraZeneca. In Jul 2009, Phase-II for Rheumatoid arthritis in USA was discontinued.

Teijin compound 1
(CAS: 1313730-14-1)

Potent CCR2b antagonist

CAS 379270-37-8 GS-7340

GS-7340
(CAS: 379270-37-8)

Tenofovir Alafenamide is a prodrug of Tenofovir, which is a reverse transcriptase inhibitor used to treat HIV and Hepatitis B. Antiviral.

CAS 106362-32-7 Peptide T

Peptide T
(CAS: 106362-32-7)

Peptide T is an HIV entry inhibitor that acts by blocking chemokine-5 receptors (CCR5), currently under clinical trials for the treatment of HIV-related neurolo...

CAS 134678-17-4 Lamivudine

Lamivudine
(CAS: 134678-17-4)

Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor, used for treatment of chronic HBV and HIV/AIDS.

CAS 35943-35-2 Triciribine

Triciribine
(CAS: 35943-35-2)

Triciribine is a potent AKT inhibitor and a cell-permeable tricyclic nucleoside molecule with potential antineoplastic activity. Akt-1, -2, and -3 are serine/th...

CAS 497223-25-3 Cenicriviroc

Cenicriviroc
(CAS: 497223-25-3)

Cenicriviroc is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell ...

CAS 288262-96-4 BX471 hydrochloride

BX471 hydrochloride
(CAS: 288262-96-4)

Potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1)

CAS 136470-78-5 Abacavir

Abacavir
(CAS: 136470-78-5)

Abacavir sulfate is a Nucleoside analog reverse transcriptase inhibitor (NRTI); guanosine analog used to treat HIV and AIDS.

CAS 864289-85-0 C 021 dihydrochloride

C 021 dihydrochloride
(CAS: 864289-85-0)

Potent CCR4 antagonist

CAS 379270-38-9 GS-7340 fumarate

GS-7340 fumarate
(CAS: 379270-38-9)

Tenofovir alafenamide fumarate, also known as Tenofovir alafenamide hemifumarate; TAF, GS-7340, is a nucleotide reverse transcriptase inhibitor and a novel pro...

JNJ 27141491
(CAS: 871313-59-6)

Potent and selective human CCR2 antagonist

D77
(CAS: 497836-10-9)

D77 is anti-HIV-1 inhibitor, which inhibits HIV-1(IIIB) replication (EC50=23.8 μM)

CH0076989
(CAS: 54371-52-9)

CH0076989 is a small molecule agonist for CCR3. It activates a number of signalling pathways including chemotaxis and receptor internalisation.

CAS 500287-72-9 Rilpivirine

Rilpivirine
(CAS: 500287-72-9)

A novel non-nucleoside reverse transcriptase inhibitor. Rilpivirine seems to be well tolerated with less CNS disturbance than Efavirenz, and has non-teratogenic...

CAS 202138-50-9 Tenofovir Disoproxil Fumarate

Tenofovir Disoproxil Fumarate
(CAS: 202138-50-9)

Tenofovir Disoproxil Fumarate belongs to a class of antiretroviral drugs, it inhibits the activity of HIV reverse transcriptase by competing with the natural su...

CAS 333352-59-3 NBD-557

NBD-557
(CAS: 333352-59-3)

NBD-557 is a N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamide analog, a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitors th...

Chemical Structure

CAS 376348-65-1 Maraviroc

Quick Inquiry

Verification code

Featured Items